Drug development for the management of organophosphorus poisoning

Expert Opinion on Drug Discovery

Volumn 8, Issue 12, 2013, Pages 1467-1477

  Elsinghorst, Paul Wilhelm ^a   Worek, Franz ^a   Thiermann, Horst ^a   Wille, Timo ^a  

^a BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

Author keywords

Bioscavenger; Cyclodextrins; Organophosphorus poisoning; Oximes

Indexed keywords

ACETYLCHOLINESTERASE; CYCLODEXTRIN; CYCLOSARIN; OBIDOXIME; ORGANOPHOSPHORUS COMPOUND; OXIME; PESTICIDE; PRALIDOXIME; ROCURONIUM; TRIMEDOXIME;

BLOOD BRAIN BARRIER; GENE TARGETING; HUMAN; IMMUNOGENICITY; INTOXICATION; META ANALYSIS (TOPIC); NEUROMUSCULAR TRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCREENING; SITE DIRECTED MUTAGENESIS;

ANIMALS; ANTIDOTES; CYCLODEXTRINS; DRUG DESIGN; HUMANS; ORGANOPHOSPHATE POISONING; OXIMES;

EID: 84889052107     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.847920     Document Type: Review

References (131)

1. Jeyaratnam J. Acute pesticide poisoning: a major global health problem. World Health Stat Q 1990;43:139-44
2. Gunnell D, Eddleston M, Phillips MR, Konradsen F. The global distribution of fatal pesticide self-poisoning: systematic review. BMC Public Health 2007;7:357
3. Szinicz L. History of chemical and biological warfare agents. Toxicology 2005;214:167-81 (Pubitemid 41406257)
4. Convention on the prohibition of the development, production, stockpiling and use of chemical weapons and on their destruction. The Hague: organisation for the prohibition of chemical weapons. Available from: www.opcw.org/ chemicalweapons-convention [Last accessed 19 September 2013]
5. Morita H, Yanagisawa N, Nakajima T, et al. Sarin poisoning in Matsumoto, Japan. Lancet 1995;346:290-3
6. MacIlwain C. Study proves Iraq used nerve gas. Nature 1993;363:3
7. Ledgard JB. A laboratory history of chemical warfare agents. Self-published, distributed by Lulu.com; Raleigh, N.C: 2006
8. Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993;58:51-66 (Pubitemid 23227698)
9. Aldridge WN, Reiner E. Enzyme inhibitors as substrates: interactions of esterases with ethers of organophosphorus and carbonic acids. Noth-Holland Pub. Co; Amsterdam: 1972
10. Holmstedt B. Pharmacology of organophosphorus cholinesterase inhibitors. Pharmacol Rev 1959;11:567-688
11. Taylor P, Radic Z, Hosea NA, et al. Structural bases for the specificity of cholinesterase catalysis and inhibition. Toxicol Lett 1995;82-83:453-8 (Pubitemid 26054735)
12. Grob D. The manifestations and treatment of poisoning due to nerve gas and other organic phosphate anticholinesterase compounds. AMA Arch Intern Med 1956;98:221-39
13. Kwong TC. Organophosphate pesticides: biochemistry and clinical toxicology. Ther Drug Monit 2002;24:144-9 (Pubitemid 34106743)
14. Lee EC. Clinical manifestations of sarin nerve gas exposure. JAMA 2003;290:659-62 (Pubitemid 37430488)
15. Eyer F, Worek F, Eyer P, et al. Obidoxime in acute organophosphate poisoning. 1: clinical effectiveness. Clin Toxicol 2009;47:798-806
16. Rahimi R, Nikfar S, Abdollahi M. Increased morbidity and mortality in acute human organophosphate-poisoned patients treated by oximes: a meta-analysis of clinical trials. Hum Exp Toxicol 2006;25:157-62
17. Karami-Mohajeri S, Nikfar S, Abdollahi M. A systematic review on the nerve-muscle electrophysiology in human organophosphorus pesticide exposure. Hum Exp Toxicol 2013;In press
18. Abdollahi M, Karami-Mohajeri S. A comprehensive review on experimental and clinical findings in intermediate syndrome caused by organophosphate poisoning. Toxicol Appl Pharmacol 2012;258:309-14
19. Childs AF, Davies DR, Green AL, Rutland JP. The reactivation by oximes and hydroxamic acids of cholinesterase inhibited by organo-phosphorus compounds. Br J Pharmacol Chemother 1955;10:462-5
20. Ginsburg S, Wilson IB. Oximes of the pyridine series. J Am Chem Soc 1957;79:481-5
21. Worek F, Thiermann H. The value of novel oximes for treatment of poisoning by organophosphorus compounds. Pharmacol Ther 2013;139:249-59
22. Buckley NA, Eddleston M, Li Y, et al. Oximes for acute organophosphate pesticide poisoning. Cochrane Database Syst Rev 2011;CD005085
23. Poziomek EJ, Hackley BE Jr, Steinberg GM. Pyridinium aldoximes. J Org Chem 1958;23:714-17
24. Lüttringhaus A, Hagedorn I. Quartäre Hydroxyiminomethylpyridiniumsalze. Drug Res 1964;14:1-5
25. Worek F, Thiermann H, Szinicz L, Eyer P. Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochem Pharmacol 2004;68:2237-48 (Pubitemid 39446151)
26. Sungur M, Guven M. Intensive care management of organophosphate insecticide poisoning. Crit Care 2001;5:211-15 (Pubitemid 32734337)
27. De Silva HJ, Wijewickrema R, Senanayake N. Does pralidoxime affect outcome of management in acute organophosphorus poisoning? Lancet 1992;339:1136-8
28. Worek F, Aurbek N, Koller M, et al. Kinetic analysis of reactivation and aging of human acetylcholinesterase inhibited by different phosphoramidates. Biochem Pharmacol 2007;73:1807-17 (Pubitemid 46601412)
29. Kassa J, Karasova J, Musilek K, Kuca K. An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice. Toxicology 2008;243:311-16 (Pubitemid 350256870)
30. Lamb JC, Steinberg GM, Hackley BE Jr. Isopropyl methylphosphonylated bisquarternary oximes; powerful inhibitors of cholinesterase. Biochim Biophys Acta 1964;89:174-6
31. Lundy PM, Hamilton MG, Sawyer TW, Mikler J. Comparative protective effects of HI-6 and MMB-4 against organophosphorous nerve agent poisoning. Toxicology 2011;285:90-6
32. Hobbiger F, Sadler PW. Protection against lethal organophosphate poisoning by quaternary pyridine aldoximes. Br J Pharmacol Chemother 1959;14:192-201
33. Stark I. Versuche zur Darstellung eines LuH6 (Toxogonin) uberlegenen Acetylcholinesterasereaktivators. PhD thesis, Albert Ludwigs Universitat, Freiburg, Germany. 1968
34. Clement JG, Shiloff JD, Gennings C. Efficacy of a combination of acetylcholinesterase reactivators, HI-6 and obidoxime, against tabun and soman poisoning of mice. Arch Toxicol 1987;61:70-5 (Pubitemid 17149979)
35. Maksimovic M, Pantelic D, Kovacev V, Binenfeld Z. Protective effects of HI-6 and toxogonin combinations in soman- and tabun-poisoned rats. Acta Pharmacol Jugoslav 1987;37:227-9 (Pubitemid 17128498)
36. Kassa J, Musilek K, Karasova JZ, et al. Two possibilities how to increase the efficacy of antidotal treatment of nerve agent poisonings. Mini Rev Med Chem 2012;12:24-34
37. Kuhnen-Clausen D, Hagedorn I, Gross G, et al. Interactions of bisquaternary pyridine salts (H-oximes) with cholinergic receptors. Arch Toxicol 1983;54:171-9 (Pubitemid 14232307)
38. Amitai G, Kloog Y, Balderman D, Sokolovsky M. The interaction of bis-pyridinium oximes with mouse brain muscarinic receptor. Biochem Pharmacol 1980;29:483-8 (Pubitemid 10212885)
39. Van Helden HP, de Lange J, Busker RW, Melchers BP. Therapy of organophosphate poisoning in the rat by direct effects of oximes unrelated to ChE reactivation. Arch Toxicol 1991;65:586-93
40. Tattersall JEH, Smith AP, Waters K, et al. Therapeutic action of HI-6 against Soman poisoning in vitro: an interspecies comparison. Br J Pharmacol 1998;125(Suppl):7P
41. Seeger T, Eichhorn M, Lindner M, et al. Restoration of soman-blocked neuromuscular transmission in human and rat muscle by the bispyridinium non-oxime MB327 in vitro. Toxicology 2012;294:80-4
42. Koniger C, Worek F, Thiermann H, Wille T. Effect of MB327 and oximes on rat intestinal smooth muscle function. Chem Biol Interact 2013;204:1-5
43. Niessen KV, Tattersall JEH, Timperley CM, et al. Competition radioligand binding assays for the investigation of bispyridinium compound affinities to the human muscarinic acetylcholine receptor subtype 5 (hM(5)). Drug Test Anal 2012;4:292-7
44. Worek F, Mast U, Kiderlen D, et al. Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta 1999;288:73-90 (Pubitemid 29472417)
45. Eyer P, Worek F. Oximes. Marrs T C, Maynard R L, Sidell F R. Chemical warfare agents: toxicology and treatment. Wiley; Weinheim. 2007. p. 305-9
46. Pohanka M, Jun D, Kuca K. Photometric microplate assay for estimation of the efficacy of paraoxon-inhibited acetylcholinesterase reactivation. J Enzyme Inhib Med Chem 2008;23:781-4
47. Wille T, Ekstrom F, Lee J-C, et al. Kinetic analysis of interactions between alkylene-linked bis-pyridiniumaldoximes and human acetylcholinesterases inhibited by various organophosphorus compounds. Biochem Pharmacol 2010;80:941-6
48. Wille T, Thiermann H, Worek F. Effect of different buffers on kinetic properties of human acetylcholinesterase and the interaction with organophosphates and oximes. Arch Toxicol 2011;85:193-8
49. Clement JG, Erhardt N. In vitro oxime-induced reactivation of various molecular forms of soman-inhibited acetylcholinesterase in striated muscle from rat, monkey and human. Arch Toxicol 1994;68:648-55 (Pubitemid 24316706)
50. Luo C, Tong M, Chilukuri N, et al. An in vitro comparative study on the reactivation of nerve agent-inhibited guinea pig and human acetylcholinesterases by oximes. Biochemistry 2007;46:11771-9 (Pubitemid 47623745)
51. Worek F, Reiter G, Eyer P, Szinicz L. Reactivation kinetics of acetylcholinesterase from different species inhibited by highly toxic organophosphates. Arch Toxicol 2002;76:523-9
52. Aurbek N, Thiermann H, Szinicz L, et al. Application of kinetic-based computer modelling to evaluate the efficacy of HI-6 in percutaneous VX poisoning. Toxicology 2006;224:74-80
53. Eyer P, Szinicz L, Thiermann H, et al. Testing of antidotes for organophosphorus compounds: experimental procedures and clinical reality. Toxicology 2007;233:108-19 (Pubitemid 46498377)
54. Boskovic B. The treatment of soman poisoning and its perspectives. Fundam Appl Toxicol 1981;1:203-13
55. Talbot BG, Anderson DR, Harris LW, et al. A comparison of in vivo and in vitro rates of aging of soman-inhibited erythrocyte acetylcholinesterase in different animal species. Drug Chem Toxicol 1988;11:289-305
56. Kuca K, Cabal J, Jun D, Musilek K. In vitro reactivation potency of acetylcholinesterase reactivators - K074 and K075 - to reactivate tabun-inhibited human brain cholinesterases. Neurotox Res 2007;11:101-6
57. Calic M, Bosak A, Kuca K, Kovarik Z. Interactions of butane, but-2-ene or xylene-like linked bispyridinium para-aldoximes with native and tabun-inhibited human cholinesterases. Chem Biol Interact 2008;175:305-8
58. Worek F, von der Wellen J, Musilek K, et al. Reactivation kinetics of a homologous series of bispyridinium bis-oximes with nerve agent-inhibited human acetylcholinesterase. Arch Toxicol 2012;86:1379-86
59. Kovarik Z, Vrdoljak AL, Berend S, et al. Evaluation of oxime K203 as antidote in tabun poisoning. Arh Hig Rada Toksikol 2009;60:19-26
60. Elsinghorst PW, Hartig W, Gundisch D, et al. A hydrazide linker strategy for heterobivalent compounds as ortho- and allosteric ligands of acetylcholine-binding proteins. Curr Top Med Chem 2011;11:2731-48
61. Eyer P, Hagedorn I, Klimmek R, et al. HLo 7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases. Arch Toxicol 1992;66:603-21
62. De Jong LP, Verhagen MA, Langenberg JP, et al. The bispyridinium-dioxime HLo-7. A potent reactivator for acetylcholinesterase inhibited by the stereoisomers of tabun and soman. Biochem Pharmacol 1989;38:633-40 (Pubitemid 19050103)
63. Luo C, Tong M, Maxwell DM, Saxena A. Comparison of oxime reactivation and aging of nerve agent-inhibited monkey and human acetylcholinesterases. Chem Biol Interact 2008;175:261-6
64. Worek F, Eyer P, Aurbek N, et al. Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxicol Appl Pharmacol 2007;219:226-34 (Pubitemid 46282867)
65. Sit RK, Radic Z, Gerardi V, et al. New structural scaffolds for centrally acting oxime reactivators of phosphylated cholinesterases. J Biol Chem 2011;286:19422-30
66. Kalisiak J, Ralph EC, Zhang J, Cashman JR. Amidine-oximes: reactivators for organophosphate exposure. J Med Chem 2011;54:3319-30
67. Shih T-M, Skovira JW, O'Donnell JC, McDonough JH. Treatment with tertiary oximes prevents seizures and improves survival following sarin intoxication. J Mol Neurosci 2010;40:63-9
68. Worek F, Thiermann H. Reactivation of organophosphate-inhibited human acetylcholinesterase by isonitrosoacetone (MINA): a kinetic analysis. Chem Biol Interact 2011;194:91-6
69. Radic Z, Sit RK, Kovarik Z, et al. Refinement of structural leads for centrally acting oxime reactivators of phosphylated cholinesterases. J Biol Chem 2012;287:11798-809
70. Mercey G, Verdelet T, Saint-Andre G, et al. First efficient uncharged reactivators for the dephosphylation of poisoned human acetylcholinesterase. Chem Commun 2011;47:5295-7
71. Chambers JE, Chambers HW, Meek EC, Pringle RB. Testing of novel brain-penetrating oxime reactivators of acetylcholinesterase inhibited by nerve agent surrogates. Chem Biol Interact 2013;203:135-8
72. Wagner S, Kufleitner J, Zensi A, et al. Nanoparticulate transport of oximes over an in vitro blood-brain barrier model. PLoS One 2010;5:e14213
73. Mochida K, Matsui Y, Ota Y, et al. Substrate specificity in the cyclodextrin-catalyzed cleavage of organic phosphates and monothiophosphates in alkaline solutions. Bull Chem Soc Jpn 1976;49:3119-23
74. Miyamoto S, Mifune A, Odaka Y, Yoneda T. Insecticidal and acaricidal cyclodextrin-(dichlorovinyl) dimethyl phosphate reaction product. Patent DE2422316. Chem Abstr 1974;82:107568
75. Brass HJ, Bender ML. Reactions of diaryl carbonates and methylphosphonates with cycloamyloses. J Am Chem Soc 1973;95:5391-9
76. Griffiths DW, Bender ML. Cycloamyloses as catalysts. Advan Catal 1973;23:209-61
77. Dodziuk H. editor. Cyclodextrins and their complexes: chemistry, analytical methods, applications.Wiley; Weinheim: 2006
78. Saenger W. Cyclodextrin inclusion compounds in research and industry. Angew Chem Int Ed 1980;19:344-62
79. Nicholson WT, Sprung J, Jankowski CJ. Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacotherapy 2007;27:1181-8 (Pubitemid 47173661)
80. Fourmentin S, Ciobanu A, Landy D, Wenz G. Space filling of b-cyclodextrin and b-cyclodextrin derivatives by volatile hydrophobic guests. Beilstein J Org Chem 2013;9:1185-91
81. Van Hooidonk C, Breebaart-Hansen JCAE. Stereospecific reaction of isopropyl methylphosphonofluoridate (sarin) with a-cyclodextrin: a model for enzyme inhibition. Recl Trav Chim Pays Bas 1970;89:289-99
82. Desire B, Saint-Andre S. Interaction of soman with b-cyclodextrin. Fundam Appl Toxicol 1986;7:646-57
83. Desire B, Saint-Andre S. Inactivation of sarin and soman by cyclodextrins in vitro. Experientia 1987;43:395-7 (Pubitemid 17060935)
84. Cabal J. Hydrolytic reactions of methylfluorophosphonates with cyclodextrins. Collect Czech Chem Commun 1995;60:1162-9
85. VanEtten RL, Clowes GA, Sebastian JF, Bender ML. The mechanism of the cycloamylose-accelerated cleavage of phenyl esters. J Am Chem Soc 1967;89:3253-62
86. Zengerle M, Brandhuber F, Schneider C, et al. Highly efficient cyclosarin degradation mediated by a b-cyclodextrin derivative containing an oxime-derived substituent. Beilstein J Org Chem 2011;7:1543-54
87. Brandhuber F, Zengerle M, Porwol L, et al. Detoxification of tabun at physiological pH mediated by substituted b-cyclodextrin and glucose derivatives containing oxime groups. Toxicology 2012;302:163-71
88. Le Provost R,Wille T, Louise L, et al. Optimized strategies to synthesize cyclodextrin-oxime conjugates as a new generation of organophosphate scavengers. Org Biomol Chem 2011;9:3026-32
89. Muller S, Estour F, Kalakuntla RK, et al. New modified b-cyclodextrin derivatives as detoxifying agents of chemical warfare agents (II). In vitro detoxification of cyclosarin (GF): general screening and toxicokinetic aspects of OP scavengers. Toxicol Lett 2013;216:206-12
90. Kalakuntla RK, Wille T, Le Provost R, et al. New modified b-cyclodextrin derivatives as detoxifying agents of chemical warfare agents (I). Synthesis and preliminary screening: evaluation of the detoxification using a half-quantitative enzymatic assay. Toxicol Lett 2013;216:200-5
91. Hoskin F, Steeves DM, Walker JE. Substituted cyclodextrin as a model for a squid enzyme that hydrolyzes the nerve gas soman. Biol Bull 1999;197:284-5 (Pubitemid 29530586)
92. Masurier N, Estour F, Froment M-T, et al. Synthesis of 2-substituted bcyclodextrin derivatives with a hydrolytic activity against the organophosphorylester paraoxon. Eur J Med Chem 2005;40:615-23 (Pubitemid 40797557)
93. Brandhuber F, Zengerle M, Porwol L, et al. Tabun scavengers based on hydroxamic acid containing cyclodextrins. Chem Commun 2013;49:3425
94. Casu B, Reggiani M, Gallo GG, Vigevani A. Conformation of O-methylated amylose and cyclodextrins. Tetrahedron 1968;24:803-21
95. Yuan D-Q, Tahara T, Chen W-H, et al. Functionalization of cyclodextrins via reactions of 2,3-anhydrocyclodextrins. J Org Chem 2003;68:9456-66 (Pubitemid 37456519)
96. Melton LD, Slessor KN. Synthesis of monosubstituted cyclohexaamyloses. Carbohydr Res 1971;18:29-37
97. Rong D, D'Souza VT. A convenient method for functionalization of the 2-position of cyclodextrins. Tetrahedron Lett 1990;31:4275-8 (Pubitemid 20227561)
98. Lepenies B, Yin J, Seeberger PH. Applications of synthetic carbohydrates to chemical biology. Curr Opin Chem Biol 2010;14:404-11
99. Bistri O, Sinay P, Sollogoub M. Sequential ring closing/opening metathesis for the highly selective synthesis of a triply bifunctionalized a-cyclodextrin. Chem Commun 2006;1112-14 (Pubitemid 43344113)
100. Butler VP. Antibodies as specific antagonists of toxins, drugs, and hormones. Pharmacol Rev 1982;34:109-14
101. Green J. Glucarpidase to combat toxic levels of methotrexate in patients. Ther Clin Risk Manag 2012;8:403-13
102. Goedde HW, Altland K. Suxamethonium sensitivity. Ann NY Acad Sci 1971;179:695-703
103. Wolfe A. Acetylcholinesterase prophylaxis against organophosphate toxicity. Fundam Appl Toxicol 1987;9:266-70 (Pubitemid 18043755)
104. Ashani Y, Shapira S, Levy D, et al. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem Pharmacol 1991;41:37-41
105. Bird SB, Dawson A, Ollis D. Enzymes and bioscavengers for prophylaxis and treatment of organophosphate poisoning. Front Biosci 2010;S2:209-20
106. Ilyushin DG, Haertley OM, Bobik TV, et al. Recombinant human butyrylcholinesterase as a new-age bioscavenger drug: development of the expression system. Acta Naturae 2013;5:73-84
107. Huang Y-J, Huang Y, Baldassarre H, et al. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci USA 2007;104:13603-8 (Pubitemid 350010655)
108. Geyer BC, Kannan L, Garnaud P-E, et al. Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents. Proc Natl Acad Sci USA 2010;107:20251-6
109. Geyer BC, Muralidharan M, Cherni I, et al. Purification of transgenic plant-derived recombinant human acetylcholinesterase-R. Chem Biol Interact 2005;157-158:331-4 (Pubitemid 41757670)
110. Chilukuri N, Sun W, Naik RS, et al. Effect of polyethylene glycol modification on the circulatory stability and immunogenicity of recombinant human butyrylcholinesterase. Chem Biol Interact 2008;175:255-60
111. Ilyushin DG, Smirnov IV, Belogurov AA Jr, et al. Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo. Proc Natl Acad Sci USA 2013;110:1243-8
112. Huang Y-J, Lundy PM, Lazaris A, et al. Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin. BMC Biotechnol 2008;8:50
113. Lichtenstein EP, Schulz KR. The effects of moisture and microorganisms on the persistence and metabolism of some organophosphorous insecticides in soils, with special emphasis on parathion. J Econ Entomol 1964;57:618-27
114. Munnecke DM, Hsieh DP. Microbial decontamination of parathion and p-nitrophenol in aqueous media. Appl Microbiol 1974;28:212-17
115. Serdar CM, Gibson DT, Munnecke DM, Lancaster JH. Plasmid involvement in parathion hydrolysis by Pseudomonas diminuta. Appl Environ Microbiol 1982;44:246-9 (Pubitemid 12068790)
116. Serdar CM, Gibson DT. Enzymatic hydrolysis of organophosphates: cloning and expression of a parathion hydrolase gene from Pseudomonas diminuta. Nat Biotechnol 1985;3:567-71
117. Nachon F, Brazzolotto X, Trovaslet M, Masson P. Progress in the development of enzyme-based nerve agent bioscavengers. Chem Biol Interact 2013;In press
118. Vilanova E, Sogorb MA. The role of phosphotriesterases in the detoxication of organophosphorus compounds. Crit Rev Toxicol 1999;29:21-57 (Pubitemid 29093408)
119. Prokop Z, Oplus?til F, DeFrank J, Damborsky J. Enzymes fight chemical weapons. Biotechnol J 2006;1:1370-80
120. Seibert CM, Raushel FM. Structural and catalytic diversity within the amidohydrolase superfamily. Biochemistry 2005;44:6383-91 (Pubitemid 40593789)
121. Blum M-M, Chen JC-H. Structural characterization of the catalytic calcium-binding site in diisopropyl fluorophosphatase (DFPase) - comparison with related b-propeller enzymes. Chem Biol Interact 2010;187:373-9
122. Harel M, Aharoni A, Gaidukov L, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004;11:412-19 (Pubitemid 38568944)
123. Tsai P-C, Fox N, Bigley AN, et al. Enzymes for the homeland defense: optimizing phosphotriesterase for the hydrolysis of organophosphate nerve agents. Biochemistry 2012;51:6463-75
124. Rochu D, Chabriere E, Masson P. Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 2007;233:47-59 (Pubitemid 46498378)
125. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 1997;349:851-2 (Pubitemid 27129220)
126. Costante M, Biggemann L, Alamneh Y, et al. Hydrolysis potential of recombinant human skin and kidney prolidase against diisopropylfluorophosphate and sarin by in vitro analysis. Toxicol In Vitro 2012;26:182-8
127. Maxwell DM, Saxena A, Gordon RK, Doctor BP. Improvements in scavenger protection against organophosphorus agents by modification of cholinesterases. Chem Biol Interact 1999;119-120:419-28 (Pubitemid 29278579)
128. Kovarik Z, Katalinic M, S ? inko G, et al. Pseudo-catalytic scavenging: searching for a suitable reactivator of phosphorylated butyrylcholinesterase. Chem Biol Interact 2010;187:167-71
129. Jun D, Musilova L, Pohanka M, et al. Reactivation of human acetylcholinesterase and butyrylcholinesterase inhibited by leptophos-oxon with different oxime reactivators in vitro. Int J Mol Sci 2010;11:2856-63
130. Cochran R, Kalisiak J, Kucukkilinc T, et al. Oxime-assisted acetylcholinesterase catalytic scavengers of organophosphates that resist aging. J Biol Chem 2011;286:29718-24
131. Radic Z, Dale T, Kovarik Z, et al. Catalytic detoxification of nerve agent and pesticide organophosphates by butyrylcholinesterase assisted with non-pyridinium oximes. Biochem J 2013;450:231-42